Today: 30 April 2026
Browse Category

NASDAQ:MNMD 18 October 2025

MindMed Stock Rockets on Breakthrough LSD Anxiety Data – Analysts Eye 100% Upside

MindMed Stock Rockets on Breakthrough LSD Anxiety Data – Analysts Eye 100% Upside

MindMed shares hit a 52-week high of $13.09 on Oct. 14, up 68% year-to-date, after its LSD-derived drug MM120 showed 48% remission in a Phase 2b anxiety trial and received FDA Breakthrough Therapy status. The company holds $237.9 million in cash and is running three Phase 3 studies, with topline results due in 2026. Most analysts rate MNMD a “Moderate Buy” with an average 12-month target near $28.
18 October 2025
·
MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

MindMed Stock Soars 15% to 52-Week High on Psychedelic Breakthrough – What’s Next for MNMD?

MindMed (NASDAQ: MNMD) closed at $13.65 on Oct. 17, up 14.6% in one day and 68% year-to-date, after its LSD-based therapy MM120 showed strong Phase 2b results for Generalized Anxiety Disorder. The FDA granted Breakthrough Therapy status to MM120, with three Phase 3 trials underway. Needham & Co. initiated coverage with a Buy rating and $28 target. MindMed holds $237.9 million in cash, funding operations into 2027.
18 October 2025
··
MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

MindMed shares hit a 52-week high of $13.09 this week after its LSD-based drug MM120 showed strong Phase 2b results for generalized anxiety disorder and received FDA Breakthrough Therapy designation. The stock is up about 68% year-to-date. Analysts set average price targets near $27.83. MindMed holds $237.9 million in cash, funding operations into 2027.
18 October 2025
··

Stock Market Today

  • Enbridge Investment Outlook Tightens as Analyst Price Targets Align Between CA$72 and CA$77
    April 29, 2026, 8:38 PM EDT. Enbridge's (TSX:ENB) fair value estimation nudged from CA$75.99 to CA$76.14 amid converging analyst price targets between CA$72 and CA$77, reflecting mixed market sentiment. Major banks like Citi, RBC Capital, and Scotiabank raised price targets based on strong Q4 results and Enbridge's diversified pipeline assets. Conversely, TD Securities and Jefferies downgraded to Hold, citing current share price strength and limited near-term earnings growth. The Canadian government's approval of Enbridge's CA$4 billion Sunrise Expansion Project on the Westcoast pipeline provides economic and employment boosts. Investors face risks including regulatory challenges after the U.S. Supreme Court rejected Enbridge's appeal, potentially impacting long-term prospects. Market watchers should monitor evolving analyst views as Enbridge's valuation debates continue.

Latest article

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

30 April 2026
Soluna Holdings filed to register the resale of about 2.46 million common shares, with no proceeds going to the company. The move follows Sazmining’s launch of a 3-megawatt Bitcoin mining operation at Soluna’s Project Dorothy 1B in West Texas. Soluna shares last traded at $1.28, up from a $1.08 Nasdaq sale price on April 28. The registered shares include 2.4 million issuable to YA II PN, LTD. via warrant exercise.
Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

30 April 2026
Brookfield Renewable Corp’s NYSE shares fell 12.5% to $35.20 on Wednesday, with volume quadrupling the three-month average ahead of first-quarter results due Friday. The drop came despite a higher quarterly dividend and mixed analyst views. The company operates 47 GW of clean energy assets globally. Analysts expect a first-quarter loss of 33.92 cents per share on $1.62 billion in revenue.
Go toTop